po tirzepatide People Who Stopped Taking the Weight Loss Drug Regained Nearly Half the Weight They Lost Tirzepatide (Zepbound, Mounjaro): Weight Loss,

People who are pregnant, breastfeeding, or dealing with certain medical conditions should avoid it

It is estimated that the Asia-Pacific region will have the highest growth rate in the GLP-1 receptor agonist market with a CAGR of 14.7% in the period between 2026 and 2035 due to the soaring levels of diabetes and obesity, growing healthcare facilities, rising disposable incomes, and increasing awareness of the new advances in diabetes management

#HimsAndHers #FDA #Peptides #HealthcareStocks #Telehealth #BiotechNews #PharmaTrends #WallStreet #HealthInnovation #StockMarketNews Read full article link in comment To view or add a comment, sign in - : The global GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 billion in 2025 at a CAGR of 13.0% during the forecast period

A risk factor increases ones chances of getting a condition compared to an individual without the risk factors